NanoViricides, Inc. (OTC BB: NNVC.OB) announced that a recent animal study of it's FluCide drug candidate, showed a quadrupling in efficacy over a previous study.
In the study, mice were aspirated with one million virus particles of the H1N1 flu virus. The mice were treated with both FluCide and Tamiflu 24 hours later. The results show that the mice treated with Tamiflu survived only 8.3 days, while the FluCide treated mice were able to hold on for 20.2 to 22.2 days.
The full announcement is here:
http://www.businesswire.com/news/home/20110321005653/en/NanoViricides-Reports-Treatment-FluCide-Drug-Candidate-Achieves
No comments:
Post a Comment